You are here

Home › Depressant fluvoxamine not effective in reducing COVID inflammation--study › Depressant fluvoxamine not effective in reducing COVID inflammation--study

Depressant fluvoxamine not effective in reducing COVID inflammation--study

Primary tabs

Depressant fluvoxamine not effective in reducing COVID inflammation--study

Tue, 2023-09-19 19:43 — mike kraft
Study shows no benefits of antidepressant for COVID-19 symptoms - UPI.com Researchers studied fluvoxamine because previous evidence suggested that it might be able to reduce inflammation caused by the virus. UPI

 

A clinical trial designed to test repurposed medications for their impact on fighting COVID-19 has found no benefit to taking the antidepressant fluvoxamine (Luvox) to ease coronavirus symptoms.

Country / Region Tags: 
Global
United States
General Topic Tags: 
COVID-19
Treatments
Disease
Research
Problem, Solution, SitRep, or ?: 
Analysis
Groups this Group Post belongs to: 
- Private group -
Workflow history
Revision ID Field name Date Old state New state name By Comment Operations
No state No state
howdy folks
Page loaded in 0.443 seconds.